ArticleJournal of inflammation research2025
Baseline Expanded Disability Status Scale Score and CD8
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate peripheral blood T cell subset characteristics and identify risk factors associated with disability progression in patients with multiple sclerosis (MS). Methods: We retrospectively analysed the clinical data of patients with MS treated at the Neurology Department of our hospital between May 2014 and August 2024. T lymphocyte subsets were assessed using flow cytometry. Patients were categorised into disability progression and non-progression groups based on changes in their Expanded Disability Status Scale (EDSS) scores from baseline to final assessment. Clinical data from both groups were analysed to identify independent risk factors for disability progression. Results: Of the patients with MS included, 68.84% had relapsing-remitting MS, with subacute onset being the most common (47.10%) and limb weakness the primary presenting symptom (34.06%). Significant differences ( Conclusion: Baseline EDSS scores and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.